Reference to it was in my TDA mobile news. WSJ short link also there.
GILD on the other side? See its incoming CEO Milligan's comments in Q&A during 4th Qtr earnings call re interest/focus on aspects of liver disease:
"... We're very interested in liver diseases, so that's a very important area for us, and we'll continue to try to bolster those to make sure that the company has the assets necessary to have the progress for the future."